FDA Approved 13 Drugs in September 2026
The U.S. Food and Drug Administration approved 13 drugs in September 2026, including first-in-class therapies, rare-disease treatments and new options for serious conditions.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
12 results loaded, newest first. End of these results.
EQS — News: Heidelberg Pharma Reports on the First Nine Months of Financial Year 2026
EQS-News: Heidelberg Pharma AG / Key word(s): 9 Month figures Heidelberg Pharma Reports on the First Nine Months of Financial Year 2026 15.10.2026 / 07:05 CET/CEST The issuer is solely responsible for the content of this announcement. ══════════════════════════════════════════════════════════════════════════ Heidelberg
VS — 7375 Demonstrates Robust Anti — Tumor Activity Across Advanced KRAS G12D — Mutant Cancers, Highlighted by 50% Confirmed ORR in 2L Pancreatic Ductal Adenocarcinoma and Two Complete Responses in 2L+ Disease (One Confirmed)
For best results when printing this announcement, please click on link below: VS-7375 Demonstrates Robust Anti-Tumor Activity Across Advanced KRAS G12D-Mutant Cancers, Highlighted by 50% Confirmed ORR in 2L Pancreatic Ductal Adenocarcinoma and Two Complete Responses in 2L+ Disease (One Confirmed) VS-7375 900 mg QD mono
Transcript: Eli Lilly Q2 2026 Earnings Conference Call
Eli Lilly (NYSE: LLY ) held its second-quarter earnings conference call on Wednesday. Below is the complete transcript from the call. APIs provide real-time access to earnings call transcripts and financial data. Visit to learn more. View the webcast at Summary Full Transcript OPERATOR Ladies and gentlemen, thank you f
Transcript: Ocugen Q2 2026 Earnings Conference Call
Ocugen (NASDAQ: OCGN ) held its second-quarter earnings conference call on Thursday. Below is the complete transcript from the call. APIs provide real-time access to earnings call transcripts and financial data. Visit to learn more. View the webcast at Summary Ocugen Inc. reported a net loss of $0.07 per share for Q2 2
Aldeyra Therapeutics to seek FDA dispute review for reproxalap
The company said it plans to submit a Formal Dispute Resolution Request to the FDA over reproxalap for dry eye disease. Aldeyra also said it now expects operational cash runway into 2029 based on reported cash and cash equivalents of $45.1 million as of June 30, 2026.
Hutchmed China says AstraZeneca submits US NDA for ORPATHYS plus TAGRISSO
The filing is for the combination in MET-driven EGFR-mutated non-small cell lung cancer. It is supported by the SAFFRON Phase III trial, which showed improvements in progression-free and overall survival, according to the company.
LEO Pharma to Showcase Its Broadest Ever Scientific Program at EADV 2026
For best results when printing this announcement, please click on link below: LEO Pharma to Showcase Its Broadest Ever Scientific Program at EADV 2026 LEO Pharma will present 28 accepted abstracts at the 2026 European Academy of Dermatology and Venereology Congress, taking place from 30 September to 3 October in Vienna
REG — BioPharma Credit PLC — Half — year Financial Report
For best results when printing this announcement, please click on link below: RNS Number: 0622W BioPharma Credit PLC 24 September 2026 24 September 2026 BIOPHARMA CREDIT PLC ("BPCR" or "the Company") HALF YEAR REPORT FOR THE YEAR ENDED 30 JUNE 2026 BioPharma Credit PLC (LSE: BPCR), the specialist life sciences debt inv
Merck's subcutaneous KEYTRUDA QLEX approved in Japan
Merck & Co.'s KEYTRUDA QLEX (pembrolizumab and berahyaluronidase alfa-pmph) injection for subcutaneous use has been approved by Japan's Ministry of Health, Labor and Welfare for all indications previously approved for KEYTRUDA. KEYJECT, the planned trademark for KEYTRUDA QLEX in Japan, can be administered in as little
Kura Oncology Q2 2026 Earnings Call Transcript
On Wednesday, Kura Oncology (NASDAQ: KURA ) discussed second-quarter financial results during its earnings call. The full transcript is provided below. APIs provide real-time access to earnings call transcripts and financial data. Visit to learn more. View the webcast at Summary Kura Oncology reported $9.1 million in n
Sanders blasts high cancer drug prices after RVMD approval
Sen. Bernie Sanders said the cost of new cancer drugs is driving financial ruin for patients, citing a 42% life-savings depletion figure without naming the source. The post followed Revolution Medicines' late-August FDA approval and reported pricing for its new pancreatic cancer therapy.